Pediatric Brain Tumor Foundation

Menu

Give Now

Updates

FDA Approves First Combination Targeted Therapy for Most Common Pediatric Brain Cancer

Low-grade gliomas are the most common pediatric brain cancer, and children with the BRAF V600 mutation typically experience poor survival outcomes and a less favorable response to chemotherapy, the current standard of care. With the FDA’s approval, Tafinlar + Mekinist is the first targeted therapy since chemotherapy that is approved as a first-line option for pediatric patients with BRAF V600E LGG.

Seizure First Aid for Pediatric Brain Tumor Families: Tips to Recognize and Help Someone Having a Seizure

A seizure can be one of the first signs of a brain tumor. They are also one of the most common late-term side effects that pediatric brain tumor patients and survivors experience after treatment. Having a seizure, or being with someone when they're having a seizure, can be terrifying.  Because seizures can affect anyone, at any age, understanding what a seizure is and how to help someone having a seizure is important knowledge for everyone. For caregivers and loved ones of a child with a brain tumor, it's essential.

American Motorcyclist Association Award Recognizes Pediatric Brain Tumor Foundation’s Community Impact

The American Motorcyclist Association (AMA) has named the Pediatric Brain Tumor Foundation the 2022 Recreational Road Riding Organizer of the Year. AMA’s annual Racing and Organizer Awards recognize standout individuals and organizations from AMA-sanctioned competition and recreational endeavors for their profound impact in the motorcycling community. The longest-running national motorcycle charity program, the Pediatric Brain Tumor Foundation’s Ride for Kids provides road and offroad riders, racers, groups, and members of the moto industry the opportunity to help families facing the deadliest childhood disease: pediatric brain cancer.

Reignited Cancer Moonshot Announces NCI-Led Initiative to Bring Clinical and Patient Navigation Support to Families Facing Childhood Cancer 

To truly end cancer as we know it, policymakers need to understand the challenges facing the childhood cancer community and commit to addressing them. In support of helping children and their families, the National Cancer Institute (NCI) is launching a first-of-its-kind, public-private partnership for pediatric-focused clinical and patient navigation support. The White House announced the Childhood Cancer – Data Integration for Research, Education, Care, and Clinical Trials (CC-DIRECT) initiative on the one-year anniversary of the reignited Cancer Moonshot. 

Ride to End the Deadliest Childhood Disease: Pediatric Brain Tumor Foundation Kicks Off 2023 Ride for Kids Season at AIMExpo

Motorcycle dealers, manufacturers, and riders will get a first look at the Pediatric Brain Tumor Foundation’s plans for this year’s Ride for Kids at the 2023 AIMExpo Powersports Tradeshow taking place Feb. 15-17 in Las Vegas.  The Pediatric Brain Tumor Foundation is partnering with powersports industry brands and community events to create new opportunities throughout the year for the motorcycling community to help families. Riders can also choose to participate in one of the Pediatric Brain Tumor Foundation’s organized rides, ride and fundraise as a group, or hit the road, track or trail as an individual. On September 17, 2023, supporters will come together to celebrate this year’s impact at National Ride for Kids Day celebrations across the country.

Pediatric Brain Tumor Foundation Welcomes Leaders from Marsh McLennan Agency and Nestlé USA to Board of Directors

The Pediatric Brain Tumor Foundation, the largest patient advocacy funder of pediatric brain tumor research and leading champion for families and survivors, announces the appointment of Peter Krause, Chief Executive Officer and President, Marsh McLennan Agency (MMA) / Southeast, and Bryan Waddell, Brand Marketing Manager, Hot Pockets, Nestlé USA, to its Board of Directors.

Pediatric Brain Tumor Foundation Participates in Strategic Forum Addressing Targeted Drug Development for MAPK Pathway Inhibitor Treatments

The Pediatric Brain Tumor Foundation participated in a multi-disciplinary forum of researchers, pharmaceutical industry representatives, patient advocacy organizations, and regulatory agency representatives from the United States and Europe, as well as the publication of the forum's findings, to address the targeted drug development for MAPK Pathway inhibitor treatments.

Load More